STEADY-PD III: Efficacy of Isradipine as a Disease Modifying Agent in Early Parkinson Disease

What is the STEADY-PD III Trial?

To study whether isradipine (an investigational drug) is effective in slowing the progression of Parkinson Disease (PD)

What are the study requirements?

  • You will have 12 in-person visits and 4 telephone visits over approximately 36 months
  • Your participation includes study-related examinations at no cost to you

Who can participate in STEADY-PD III?

If you or someone you care about can answer "yes" to the questions below, you or they may be eligible for study participation.

  • Do you have early idiopathic Parkinson disease, diagnosed within the last 3 years?
  • Were you at least 30 years old at the time of diagnosis?
  • Are you not currently receiving dopaminergic therapy?

If you are interested in knowing more about this clinical trial, please contact:

Amber Servi
Study Coordinator
212.305.3938
ads2178@columbia.edu